| 1 |
35346662 | Hydroquinone destabilizes BIM mRNA through upregulation of p62 in chronic myeloid leukemia cells. | 2022 May |
1 |
| 2 |
32424251 | Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib. | 2020 May 18 |
1 |
| 3 |
30614795 | The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer. | 2019 |
3 |
| 4 |
31031856 | Dual-Inhibition of mTOR and Bcl-2 Enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma In Vitro and In Vivo. | 2019 |
1 |
| 5 |
30596398 | Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1. | 2018 Dec |
1 |
| 6 |
28350129 | Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP. | 2017 Apr |
1 |
| 7 |
29156797 | JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer. | 2017 Oct 17 |
2 |
| 8 |
29263915 | Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. | 2017 |
3 |
| 9 |
29340082 | Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax. | 2017 Dec 19 |
1 |
| 10 |
26493374 | Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding. | 2016 Feb |
1 |
| 11 |
26874859 | Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma. | 2016 Feb 13 |
1 |
| 12 |
27103402 | Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. | 2016 Sep 1 |
5 |
| 13 |
27512118 | Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro. | 2016 Oct |
1 |
| 14 |
27678524 | A microtubule inhibitor, ABT-751, induces autophagy and delays apoptosis in Huh-7 cells. | 2016 Nov 15 |
1 |
| 15 |
25737542 | Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. | 2015 Mar 17 |
1 |
| 16 |
26245900 | The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism. | 2015 Sep 25 |
1 |
| 17 |
26447615 | Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer. | 2015 Nov 3 |
1 |
| 18 |
24402163 | Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. | 2014 Jun |
1 |
| 19 |
23234544 | The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. | 2013 Mar 1 |
1 |
| 20 |
24097825 | Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. | 2013 Dec 1 |
2 |
| 21 |
24120870 | BIM-mediated membrane insertion of the BAK pore domain is an essential requirement for apoptosis. | 2013 Oct 31 |
1 |
| 22 |
22525702 | Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. | 2012 Jun 15 |
1 |
| 23 |
22538851 | Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. | 2012 Jun 14 |
2 |
| 24 |
23285061 | ABT-737 induces Bim expression via JNK signaling pathway and its effect on the radiation sensitivity of HeLa cells. | 2012 |
1 |
| 25 |
21628457 | Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. | 2011 Jul 15 |
1 |
| 26 |
21659544 | Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. | 2011 Aug 4 |
1 |
| 27 |
21697949 | The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. | 2011 Jun 23 |
1 |
| 28 |
20038611 | The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. | 2010 Mar |
1 |
| 29 |
19641525 | The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. | 2009 Nov |
1 |
| 30 |
19805519 | Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. | 2009 Dec |
2 |
| 31 |
19088028 | Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. | 2008 Dec 15 |
1 |
| 32 |
17283153 | Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. | 2007 Feb 1 |
1 |